Adopting intensive lifestyle changes can slow or stop progression of early-stage Alzheimer’s disease, according to a new ...

People who follow a MIND diet, even if started later in life, were significantly less likely to develop Alzheimer's disease or related forms of dementia, according to new research.

Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...

Brain scans capture memory formation in babies, raising new questions about why people forget their earliest years ...

Caregiving is a tough job that affects everyone, regardless of their celebrity or financial status. That's why some big names ...

Dementia, a condition impacting memory and cognitive functions, poses a significant global health challenge. Research ...

Lecanemab, approved by the FDA in 2023 to treat early Alzheimer's disease, is a monoclonal antibody that binds with high affinity to amyloid-beta soluble protofibrils. In the phase III CLARITY-AD ...

June is Alzheimer’s and Brain Awareness month. Nearly seven million Americans are living with Alzheimer’s. By 2050, this number is projected to rise to nearly 13 million.

While Alzheimer’s is a specific disease and the most common cause of dementia, dementia is a broader, "umbrella term that describes a collection of cognitive, functional and behavioral symptoms ...

Among individuals with Alzheimer’s disease or other dementias, common and challenging behaviors occur because of changes in the brain during the disease progression that affect cognitive ...

In a real-world study, infusion-related reactions occurred in 37% of Alzheimer's patients treated with lecanemab. Amyloid-related imaging abnormalities (ARIA) emerged in 22% of treated patients.